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The yeast anaphase-promoting complex (APC) subunitMnd2
is necessary for maintaining sister chromatid cohesion in
prophase I of meiosis by inhibiting premature ubiquitination
and subsequent degradation of substrates by theAPCAma1 ubiq-
uitin ligase. In a proteomics screen for post-translational mod-
ifications on the APC, we discovered that Mnd2 is phosphoryl-
ated during mitosis in a cell cycle-dependent manner. We
identified and characterized the sites ofmitoticMnd2 phospho-
rylation during the cell cycle. Collective mutation of Mnd2
phosphorylation sites to alanine had no effect on vegetative
growth but a striking effect (>85% reduction) on the percentage
of tetrad-forming cells compared with the wild type strain. Sim-
ilar to the MND2 deletion strain, cells harboring the alanine
mutant that did not form spores arrested after premeiotic S
phase with a single undivided nucleus and low levels of the
APCAma1 meiotic substrate, Clb5, relative to wild type cells. In
contrast, collective mutation of Mnd2 phosphorylation sites to
aspartic acid resulted in partial suppression of the sporulation
defect. No differences were observed in the binding between
eachMnd2 isoform and the APC in vitro. However, in vivo, we
observed a gradient in the abundance of APC-associated
Mnd2 in each strain that was proportional to the observed
differences in sporulation and Clb5 levels. Taken together,
these data suggest that mitotic phosphorylation of Mnd2 is
necessary for APC-mediated progression beyond the first
meiotic nuclear division.
Proper progression through the eukaryotic cell cycle is
achieved in large part through coordinated regulation of pro-
tein degradationmediated by E32 ubiquitin ligases (for a review,
see Refs. 1–4). During mitosis and meiosis, targeted protein
degradation is tightly associated with the organization of chro-
mosomes and their equivalent distribution into two separate
progeny cells during anaphase and is controlled by a multisub-
unit ubiquitin ligase called the anaphase-promoting complex
(APC) (5–7). As an E3 ligase, the APC transfers ubiquitin onto
lysine residues of substrate proteins in an iterative manner that
forms polyubiquitin chains on the surface of a substrate protein
(8, 9). The polyubiquitinated substrate is then recognized by the
26 S proteosome and degraded, while the ubiquitin is recycled.
The APC is itself regulated, ensuring that the timing of sub-
strate degradation is tied to the completion of other cellular
processes. Indeed misregulation of the APC can lead to disas-
trous results including cell cycle arrest or improper chromo-
some segregation and cell death (10–12).
Regulation of the APC during mitosis is accomplished by
several mechanisms, including the association of co-activator
proteins and through phosphorylation of individual subunits
within the complex. Two co-activator proteins, Cdc20 and
Cdh1, facilitate the association of substrate proteins with the
APC at different stages of the mitotic cell cycle (13–17). Each
co-activator is regulated through mechanisms involving both
phosphorylation and protein-protein interactions (15–21).
Additionally specific subunits of theAPCare phosphorylated in
a cell cycle-dependent manner, which has been shown to
enhance binding and activation by Cdc20 (22–24). APC sub-
unitphosphorylationiscontrolledinlargepartbymitoticcyclin-
dependent kinase activated by the Clb2 cyclin, which is later
targeted for destruction by the APC upon exit frommitosis (25,
26). As a result, the APC exists in a hyperphosphorylated state
during mitosis and a hypophosphorylated state during G1
phase.Mutation of the cyclin-dependent kinase consensus sites
in the APC subunits Cdc16, Cdc27, and Cdc23 results in
reduced APCCdc20 activity toward Clb2 in vivo as well as a delay
in the onset of anaphase (25, 26). Currently there is no evidence
that mutation of knownmitotic APC phosphorylation sites will
have detrimental effects on meiotic cell cycle transitions.
In budding yeast the APC is regulated during meiosis not
only by Cdc20 and Cdh1 co-activators but also by a meiosis-
specific co-activator called Ama1 (27, 28), which is necessary
for spore wall assembly and expression of late meiotic genes
(29).AMA1 gene transcription and splicing occurs only inmei-
otic cells (29) and begins during premeiotic S phase (30). How-
ever, the co-activator is selectively inhibited early in meiosis by
the APC subunit Mnd2 (30, 31).
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Mnd2 is found in complex with the APC during both the
mitotic and meiotic cell cycles (32–34). Yeast lacking Mnd2
proceed normally through the mitotic cell cycle but are unable
to complete sporulation, arresting before the first meiotic
nuclear division with uncondensed chromatin (35). Recent evi-
dence has shown thatMnd2 specifically inhibitsAPCactivation
by Ama1 during prophase I. In cells lackingMnd2, uninhibited
APCAma1 prematurely targets securin (Pds1) for degradation,
which results in the premature separation of sister chromatids
due to unrestrained separase (Esp1) activity (30), followed by
cell cycle arrest. Uninhibited APCAma1 was also found to con-
trol the degradation of Clb5 duringmeiosis. Although inhibited
early in meiosis, APCAma1 becomes active during anaphase I
despite the presence of Mnd2, suggesting that the inhibitory
function of Mnd2 is regulated post-translationally. Further-
more it has been suggested that regulation of Mnd2 might be
linked to its phosphorylation status (30).
In a screen for cell cycle-dependent post-translational mod-
ifications that occur on the APC during mitosis, we discovered
that Mnd2 is one of five major phosphorylated subunits in the
complex. Here we show the identity of Mnd2 phosphorylation
sites and their relative changes during the cell cycle using mass
spectrometry. To determine the functional significance of
Mnd2 phosphorylation, we used site-directed mutagenesis to
generate yeast strains harboring Mnd2 phosphorylation site
mutants and then tested these mutants for their ability to pro-
gress through mitosis or meiosis. Vegetative growth of mnd2
phosphorylation site mutants was unperturbed. However,
sporulation of a mnd2-(S/T-A) strain was severely compro-
mised, whereas reciprocal mutation to aspartic acid partially
suppressed the sporulation defect. The defects in sporulation of
the alanine mutant were consistent with those of the deletion
strain, including arrest before the first meiotic nuclear division
and reduced ability to accumulate Clb5. The sporulation defect
of the alanine mutant strain can be explained by the relatively
low levels of mnd2-(S/T-A) found in APC co-precipitations
compared with the aspartic acid mutant and wild type Mnd2
isoforms in vivo. However, in vitro binding between the APC
and each Mnd2 isoform was found to be almost identical, and
treatment of the APC with phosphatase did not eliminate
Mnd2 co-precipitation, suggesting that phosphorylation may
be necessary tomaintain the stability ofMnd2 before entry into
meiosis. Taken together, these data support a role for mitotic
phosphorylation in the regulation of Mnd2 as an APCAma1
inhibitor in early meiosis.
EXPERIMENTAL PROCEDURES
Plasmid and Strain Construction—Standardmethods for the
growth, maintenance, and transformation of yeast and bacteria
and for the manipulation of DNA were used. All constructed
plasmids were verified by DNA sequencing. Yeast strains used
in this study are listed in Table 1. Strain W1588-4c is a deriva-
tive of W303 in which the weak rad5 mutation has been
repaired (36). Strains expressing Cdc27 and Mnd2 with C-ter-
minal 3 FLAG epitopes were constructed by integrating PCR
amplicons amplified from p3FLAG-KanMX plasmid (a gift
from Dr. Toshio Ysukiyama, Fred Hutchinson Cancer Center)
into the yeast genome as described previously (37). The Apc1-
TAP strain was generated by integration of PCR amplicons
from pBS1539 as described previously (38). Construction of
phosphorylation site mutations in MND2 was accomplished
using the QuikChange multisite-directed mutagenesis kit
(Stratagene) according to the manufacturer’s specifications
(oligonucleotide sequences are available upon request). Muta-
tions were made and sequenced in pIVEX-FLAG-MND2 in
which theMND2 open reading framewas originally cloned into
the NotI/SalI sites (34). After mutagenesis, the XhoI fragment
from pIVEX-FLAG-MND2 or pIVEX-FLAG-mnd2 phospho-
rylation sitemutant (containing all 14mutations within the last
702 base pairs of the open reading frame) was subcloned into
the XhoI site of pMT004, a pRS404 vector containing the first
405 base pairs of the MND2 open reading frame (up to the
naturally existing XhoI site) and 500 base pairs of the upstream
promoter region. The resulting wild type, S/T-A mutant, and
TABLE 1
S. cerevisiae strains used in this study
Strain Relevant genotype Source
W1588-4ca MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 R. Rothstein
DLY3033 MATa cdc15-2 bar1::URA3 J. Pringle
RSY333 MATa cyh2 ho::LYS2 leu2::hisG lys2 trp1::hisG ura3-1 R. Strich
RSY335 MATa/a cyh2 ho::LYS2 leu2::hisG lys2 trp1::hisG ura3-1 R. Strich
YKA152a MND2-3FLAG:KanMX4 This Study
YKA155a CDC27-3FLAG:KanMX4 bar1::URA3 This Study
YKA156b CDC27-3FLAG:KanMX4 This Study
YKA181a APC1-TAP:URA3 CDC27-3FLAG:KanMX4 This Study
YKA191a APC2-TAP:URA3 MND2-3FLAG:KanMX4 This Study
YKA311c mnd2::KanMX4 This Study
YKA312c mnd2::KanMX4 trp1::pRS404-mnd2(S/T-A)-TRP1 This Study
YKA313c mnd2::KanMX4 trp1::pRS404-MND2-TRP1 This Study
YKA314c mnd2::KanMX4 trp1::pRS404-mnd2(S/T-D)-TRP1 This Study
YKA315c mnd2::KanMX4 Ycp50::HO This Study
YKA316c mnd2::KanMX4 trp1::pRS404-mnd2(S/T-A)-TRP1 Ycp50::HO This Study
YKA317c mnd2::KanMX4 trp1::pRS404-MND2-TRP1 Ycp50::HO This Study
YKA318c mnd2::KanMX4 trp1::pRS404-mnd2(S/T-D)-TRP1 Ycp50::HO This Study
YKA321a CDC27-3FLAG:KanMX4 mnd2 This Study
YKA331a CDC27-3FLAG:KanMX4 mnd2 trp1::pRS404-MND2-TRP1 This Study
YKA332a CDC27-3FLAG:KanMX4 mnd2 trp1::pRS404-mnd2(S/T-A)-TRP1 This Study
YKA333a CDC27-3FLAG:KanMX4 mnd2 trp1::pRS404-mnd2(S/T-D)-TRP1 This Study
a Derived fromW1588-4c, which is a derivative of W303 in which the weak rad5mutation has been repaired (see “Experimental Procedures”).
b Derived from DLY3033.
c Derived from RSY333.
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S/T-Dmutant plasmids were linearized with HindIII and inte-
grated into the trp locus of YKA311 in which the open reading
frame forMND2 in the high efficiency sporulating yeast strain
RSY333 was replaced with KanMX4 by PCR-mediated trans-
formation (29). Diploid strains were created by transformation
with YCp50::HO (HO mothallic switching endonuclease) and
selecting for transformants on synthetic dextrose lacking uracil
(SD-URA). Successful conversion to diploid was confirmed by
flow cytometry.
Cell Cycle Arrests—To arrest cells in G1 phase, cultures were
first grown for two generations in YPDmedium asmeasured by
absorbance at 600 nm (corresponding to growth from A600 
0.2–0.8) followed by addition of synthetic -factor peptide
(University of North Carolina peptide synthesis facility) to a
final concentration of 50 g/liter. For M phase arrests in the
temperature-sensitive strain YKA156, cells were grown for two
generations at the permissive temperature (27 °C) and arrested
by shifting the temperature to 37 °C, which results in late M
phase arrest (39–41). The degree of cell cycle arrest wasmon-
itored by phase-contrast microscopy, and cells were har-
vested by centrifugation after 90% of the culture reached
the desired morphology (unbudded for G1 arrest and equiv-
alently budded for M arrest). Harvested cells were washed
once with deionized water, centrifuged once more, and fro-
zen at 80 °C overnight prior to protein purification.
Affinity Purifications and Phosphatase Assays—Yeast cells
were lysed at 4 °C in prechilled lysis buffer containing 25 mM
HEPES-NaOH, pH 7.5 (Fisher), 400 mM NaCl (Sigma), 10%
glycerol (Fisher), 0.5 mM dithiothreitol (Sigma), 0.1% Triton
X-100 (Sigma), 50 mM NaF (Sigma), 1.3 mM activated sodium
ortho-vanadate (Sigma), 50 mM -glycerophosphate (Spec-
trum), 0.5 mM phenylmethylsulfonyl fluoride (Roche Applied
Science), and Complete protease inhibitor tablets (Roche
Applied Science). All purification steps were conducted at 4 °C.
Approximately 1011 cells were lysed with 0.5-mmglass beads in
200 ml of lysis buffer using a bead beater (Biospec Products
Inc.) operated for 6 1.25-min pulseswith 5-min rest intervals.
The resulting extract was cleared by centrifugation at 92,000 
g for 1 h. The cleared extract was incubated on a rotisserie for
3 h with a 200-l bead volume of EZview Red anti-FLAG M2
affinity matrix (Sigma) equilibrated with lysis buffer. After
incubation, the affinity matrix was harvested by centrifugation
and washed 4  10 min with 25 ml of lysis buffer. For experi-
ments in which the APC was separated by HPLC, the beads
were washed another 4  10 min with 25 ml of detergent-free
buffer containing 25 mM sodium phosphate buffer, pH 7.5, 400
mMNaCl, 10%glycerol, and all phosphatase andprotease inhib-
itors described earlier. The APC was eluted from the affinity
matrix by two 10-min incubations at 30 °C and 950-rpm shak-
ing with a bead-equivalent volume of 0.5mg/ml 3 FLAG pep-
tide (Sigma-Aldrich) dissolved in either lysis buffer or deter-
gent-free sodium phosphate buffer.
Phosphatase assays on full-length proteinwere conducted on
theAPCdirectly bound to the affinitymatrix afterwashingwith
detergent-free sodium phosphate buffer. The affinity matrix
was first conditioned 4 7minwith 1ml of phosphatase buffer
containing 50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 2 mM
MnCl2. Next thematrix was split, and one-half was treatedwith
1000 units of -phosphatase dissolved in 1 bead-equivalent vol-
ume of phosphatase buffer at 30 °C for 30min. Both halveswere
then washed 2  7minwith 1ml of detergent-free sodiumphos-
phate buffer, and the APCwas eluted as described above.Matrix-
assisted laser desorption ionization (MALDI) target phosphatase
assays were conducted as described previously (42).
GST Fusion Protein—MND2 wild type, S/T-A, or S/T-D
genes were subcloned into pGEX-4T1 by PCR from the pRS404
vectors harboring each gene isoform. The resulting N-terminal
GST fusion constructs were overexpressed in BL21 pLysS cells
according to the manufacturer’s protocol (Stratagene). Cells
were lysed by sonication in 1 phosphate-buffered saline and
cleared by centrifugation. GST fusion proteins were purified
from the cell lysate by batch incubation with glutathione-
SepharoseTM 4B (Amersham Biosciences). Each GST fusion
protein was digested with trypsin to verify length and sequence
by MALDI-time of flight (TOF) MS.
Chromatography—Full-lengthAPC subunits eluted from the
affinity matrix were fractionated by reverse-phase HPLC using
an Agilent 1100 series HPLC instrument coupled to a C4 Mass
Spec reverse-phase column (Vydac), an 1100 seriesUV spectro-
photometer (Agilent), and a Foxy 200 fraction collector (ISCO
Inc.). Conditions forHPLC separationwere as follows: bufferA,
5% acetonitrile (ACN), 0.1% trifluoroacetic acid; buffer B, 95%
ACN, 0.09% trifluoroacetic acid; gradient, 5% B for 5 min,
5–65% B in 65 min, and 65- 95% B in 10 min. Fractions were
collected every minute, frozen at 80 °C, and lyophilized.
In-gel digestion with porcine trypsin was conducted as
described previously (43). Separation of tryptic peptides was
accomplished by capillary HPLC using an Agilent 1100 series
capillary liquid chromatography system with PepMap C18 col-
umn (LC Packings) connected in line with a Probot MALDI
target microfraction collector (LC Packings) (44).
Mass Spectrometry—Lyophilized C4 HPLC fractions con-
taining full-length Mnd2 were reconstituted in 5 l of 85%
ACN, 0.1% trifluoroacetic acid, and one-tenth of the sample
was prepared forMALDI-TOFMSby the dried dropletmethod
with a saturated solution of sinapic acid (Fluka) in 50% ACN,
0.1% trifluoroacetic acid. The reconstituted sample was then
analyzed directly on a Reflex III MALDI-TOF mass spectrom-
eter (Bruker Daltonics Inc.) operating in linear mode. Linear
mode MALDI-TOF mass spectra were obtained immediately
after calibrating the mass spectrometer using a mixture of
bovine serum albumin (Sigma) and cytochrome c (Sigma) that
was spotted in close proximity to the sample. Liquid chroma-
tography microfractions were analyzed on an ABI 4700
MALDI-TOF/TOF mass spectrometer (Applied Biosystems
Inc.) using a saturated solution of recrystallized -cyano-4-hy-
droxycinnamic acid in 50% ACN, 0.1% trifluoroacetic acid as
the matrix.
In Vivo 32P Labeling—Yeast strains were labeled with
monosodium [32P]phosphate in vivo as described previously
(26). Briefly saturated overnight 5-ml cultures were diluted to
A600  0.2 in 50ml of YPD and allowed to grow toA600  0.6 at
which timeMe2SOwas added to 1%.AtA600 0.8, each culture
was arrested inM phase by addition of nocodazole to 15 g/ml
or in G1 phase by addition of -factor as described above (see
“Cell Cycle Arrests”). After arresting for 3 h, cells were har-
Mnd2 Phosphorylation Is Necessary for Meiosis I Progression
JUNE 15, 2007 • VOLUME 282 • NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 17353
vested by centrifugation, washed once with sterile water, and
resuspended in 35 ml of synthetic complete medium lacking
phosphate and containing Me2SO, nocodazole, and 1 mCi of
NaH232PO4 (ICN Inc.). After labeling for 1 h at 30 °C, cells were
collected by centrifugation, washed once with water, trans-
ferred to a 2-ml screw cap tube, and frozen at 80 °C.
Cells were lysed by adding cell pellet-equivalent volumes of
lysis buffer and 0.5-mm glass beads to the pellet and vortexing
6  2 min at maximum power with 5-min rest intervals on ice.
All following steps were conducted at 4 °C. The extract was
cleared by centrifugation in a microcentrifuge at 16,100  g for
20 min, and the supernatant was transferred to a fresh 2-ml
screw cap tube followed by affinity purification as described
above. The APC was eluted as described above and then pre-
cipitated to remove excess volume and salt by adding 10 vol-
umes of cold acetone and incubating at 20 °C overnight. The
precipitate was collected by centrifugation at 16,100  g for 20
min, air-dried at room temperature, and then resuspended in
1 lithiumdodecyl sulfate loading buffer (Invitrogen Inc.) con-
taining 100 mM dithiothreitol. The sample was separated on a
precast 4–12% BisTris acrylamide gel (Invitrogen), dried, and
exposed to a storage phosphor screen for analysis by Phosphor-
Imager (Storm, Amersham Biosciences).
Growth Curves, Sporulation Assays, and Western Blotting—
To measure relative growth rates of strains harboring mnd2
phosphorylation site mutants or complete open reading frame
deletions, saturated overnight cultures grown in YPD medium
were diluted 20-fold into 5ml of fresh YPDmedium and grown
for 1 or 3 h at 30 or 37 °C, respectively. Each culture was then
diluted to A660  0.025 (3  105 cells/ml) in three separate
tubes with 5 ml of fresh YPDmedium and grown at 30 or 37 °C
for 8–9 h. Growth was monitored every 2 h by measuring the
absorbance at 660 nm with a SmartSpec 3000 spectrophotom-
eter (Bio-Rad).
To induce sporulation, single colonies picked from YP-glyc-
erol agar plates were spread over the entire surface of a fresh
YPD agar plate and grown for 24 h at 30 °C, ensuring that over-
night growth saturated the YPD plate. All following steps were
conducted at 30 °C. The YPD plates were replica-plated to pre-
sporulation agar plates (1% potassium acetate, 1% yeast extract,
2% peptone) until 95% of the cell population were unbudded
(23–24 h) as counted using a hemacytometer followed by rep-
lica-plating to sporulation medium (SPM) agar plates (1%
potassiumacetate, 0.1% yeast extract, 0.05%dextrose). The per-
centage of tetrads was monitored by light microscopy using a
hemacytometer. Cells were collected by gently scraping a frac-
tion of the cells followed by resuspension in water, centrifuga-
tion, snap freezing the pellet in a dry ice/ethanol bath, and stor-
age at80 °C (forWestern blots). Additionally an aliquot of the
scraped cellswas resuspended in 70%ethanol (for fluorescence-
activated cell sorting or fluorescence microscopy).
Protein levels were analyzed byWestern blotting after break-
ing cells with glass beads in trichloroacetic acid lysis buffer (10
mM Tris-HCl, pH 8.0, 25 mM ammonium acetate, 1 mM
Na2EDTA, 10% trichloroacetic acid). The trichloroacetic acid-
precipitated protein pellet was dissolved in resuspension solu-
tion (3% SDS, 100mMTris-HCl, pH 11.0), and the total protein
concentration of each sample was quantified by absorbance at
750 nm using a DC protein assay kit (Bio-Rad). For normalized
comparison, 40 g of total protein was loaded in each lane.
Primary antibodies to Clb5 (Santa Cruz Biotechnology
sc-20170; 1:1000) or custom rabbit Mnd2 N terminus antibod-
ies (-Mnd2) (Sigma Genosys) were used in PBS-T (1 phos-
phate-buffered saline, 0.1% Tween) with 5% nonfat dried milk.
Detection of bound primary antibody was accomplished with
an ECL-Plus chemiluminescence detection kit (Amersham
Biosciences) and horseradish peroxidase-conjugated goat anti-
rabbit secondary antibody (Chemicon International). The cus-
tom antibody was verified to bind each Mnd2 isoform equiva-
lently for Western blot detection.
Fluorescence Microscopy and Flow Cytometry—Cells fixed in
70% ethanol were harvested by centrifugation, washed twice,
and resuspended in 1 phosphate-buffered saline at 25 °C.
Approximately 10l of the cell suspensionwas adsorbed onto a
poly(L-lysine) glass microscope slide for 5 min after which the
excess suspension was removed and replaced with 10 l of
DAPI solution (2 g/ml) for 5 min. After removal of the excess
DAPI solution, each sample was washed twice for 2minwith 30
l of 1 phosphate-buffered saline and allowed to dry at room
temperature. Finally 10 l of mounting solution (90% glycerol,
1 mg/ml p-phenylenediamine, 20 ng/ml DAPI) was added to
the top of each sample, covered with a coverslip, and com-
pressed with weight for at least 1 h. Cells were imaged by dif-
ferential interference contrast or by fluorescence detection of
DAPI-stained nuclei. Measurements of cellular DNA content
were collected on a FACScan flow cytometer as described pre-
viously (34).
RESULTS
Mnd2 Is Hyperphosphorylated in Vivo during Mitosis—Re-
cent mass spectrometric analyses have shown that at least five
of 11 different human APC subunits are phosphorylated on a
total of 43 different Ser or Thr residues, many of which are
differentially phosphorylated in a cell cycle-dependent manner
(45). In comparison, only three of 13APC subunits in yeast have
been shown to be phosphorylated in vivo (25, 26), and although
specific sites have been inferred from canonical cyclin-depend-
ent kinase consensus sequences, there has not been a focused
proteomics scale analysis of APC subunits thus far. Therefore,
to reveal the presence of previously unknown post-transla-
tional modifications on the APC (including phosphorylation),
we measured the full-length molecular weights of individual
APC subunits by MALDI-TOF MS and compared these meas-
urements to the calculated masses of each subunit based on
sequence information found in the Saccharomyces Genome
Database (www.yeastgenome.org/). When conducting these
analyses with APC purified from yeast arrested inMphase with
nocodazole we discovered a 392-Da positive shift (m/z 43,217)
in the apex mass of the subunit Mnd2 with respect to the cal-
culated molecular mass (munmodified  42,825 Da), suggesting
that Mnd2 was post-translationally modified in M phase. We
repeated this experiment with cells arrested in G1 phase and
found only a modest positive mass shift of 94 Da (m/z 42,919)
relative to the calculated molecular weight (Fig. 1A). The mass
deviation ofMnd2 betweenG1 andMphases (m/zG1 m/zM 
298) was the largest of any subunit we measured (data not
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shown) and suggested that the modification was cell cycle-
dependent. Next we determined whether Mnd2 could be
metabolically labeled with NaH232PO4 in yeast arrested in M
phase with nocodazole or in G1 with -factor. A comparison
of FLAG affinity purifications from metabolically labeled
yeast with or without a C-terminal
3 FLAG tag on the APC subunit
Cdc27 is shown (Fig. 1B). Similar
to previous reports, APC subunit
phosphorylation was much higher
in M phase compared with G1
phase. In nocodazole-arrested
cells, we observed six distinct
bands unique to the tagged strain
that did not appear in the purifica-
tion from a strain lacking a 3
FLAG tag. Alignment of the phos-
phorimage with a Coomassie-
stained large scale purification of
the APC from nocodazole-ar-
rested cells revealed the identity of
the known phosphorylated sub-
units Cdc16, Cdc27, and Cdc23. In
addition, we observed phospho-
proteins that aligned with Apc1,
Apc2, and Mnd2. To verify the
identity of these three phospho-
proteins, we introduced epitope
tags onto the C termini of Apc1
(Apc1-TAP in Cdc27-3 FLAG
background), Mnd2 (Mnd2-3
FLAG), and Apc2 (Apc2-TAP in
Mnd2-3 FLAG background),
which would create a gel mobility
shift in the 32P-labeled phospho-
protein band in question if the
identity was assigned correctly.
Each tagged strain was metaboli-
cally labeled in the presence of
nocodazole, and the resulting
FLAG affinity purification was
compared with the original
Cdc27-3 FLAG 32P-labeled puri-
fication. We observed a shift in gel
mobility for the phosphoproteins
provisionally assigned to Apc1 and
Mnd2 (Fig. 1C). However, no shift
was observed for the band assigned
to Apc2 (data not shown).
To determine whether the apex
mass shift observed between the
Mnd2 MALDI mass spectra was
completely or partially due to phos-
phorylation and to estimate the
number of phosphorylation sites
involved, we compared the full-
length molecular weights of Mnd2
in M phase by MALDI-TOF MS
before and after treatment with -phosphatase. Nocodazole
induces a mitotic checkpoint arrest by inhibiting microtubule
polymerization, whichmay induce phosphorylation of proteins
that would not normally be phosphorylated during an unper-
turbed mitotic progression. Therefore, in this experiment, we
FIGURE 1. Mnd2 is a differentially phosphorylated component of the APC in mitotic cells. A, overlaid
MALDI-TOF mass spectra of Mnd2 in G1 and M phases of the mitotic cell cycle. Mnd2 was co-purified with the
APC from yeast harboring epitope-tagged Cdc27 and arrested in G1 phase with -factor or in M phase with
nocodazole followed by HPLC separation and linear mode MS analysis. B, SDS-PAGE separation of APC purified
from yeast arrested in G1 phase with -factor or in M phase with nocodazole and labeled metabolically with
32PO4 in vivo or stained with Coomassie. The identity of relevant APC subunits in the Coomassie-stained gel is
indicated. Cells lacking an epitope tag on Cdc27 (no tag control, NTC) were compared in parallel to allow
discrimination of nonspecific radiolabeled protein bands. C, SDS-PAGE mobility comparison between 32P-
labeled APC subunits with (, TAP or 3FLAG) and without () C-terminal epitope tags. In the  lane, APC was
purified from YKA155 harboring a 3 FLAG epitope C-terminal to Cdc27. In the  lane, APC was purified by
FLAG immunoprecipitation from the doubly tagged strain YKA181 (CDC27-3 FLAG, APC1-TAP) or the singly
tagged strain YKA152 (MND2-3 FLAG). D, overlaid MALDI-TOF mass spectrum of Mnd2 in G1 and M phases of
the mitotic cell cycle before and after treatment with -phosphatase (P). Mnd2 was co-purified with the APC
from the temperature-sensitive yeast strain YKA156 (cdc15-2) arrested in G1 phase with -factor or in M phase
by temperature shift. While still bound to FLAG affinity matrix, the purifications were split, and half of the
purification was treated with -phosphatase followed by HPLC separation and linear mode MS analysis of both
phosphorylated and dephosphorylated proteins.
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opted to use a strain that harbors a temperature-sensitivemuta-
tion in the mitotic exit network kinase Cdc15. We have used
this strain successfully in the past to characterize phosphoryla-
tion of the APC co-activator Cdh1 (46). APC purifications from
yeast arrested in G1 orM phase cells were split, and half of each
purification was treated with -phosphatase. The apex mass of
Mnd2 from M phase cells was 43,221 Da before phosphatase
treatment and shifted to a mass of 42,837 Da after phosphatase
treatment; this is within 12 Da of the calculated mass of the
unmodified protein and indicated that the entire mass shift
observed in M phase is due to phosphorylation (Fig. 1D). In
comparison, the apex mass of Mnd2 from G1 phase cells was
42,926 Da before phosphatase treatment and was shifted to
42,825Da after phosphatase treatment, indicating thatMnd2 is
less phosphorylated during G1 phase compared with M phase.
Dividing the average mass difference between the measure-
ments made before and after phosphatase treatment (m 
mp  mdp) by the mass of a single phosphorylation modifica-
tion (HPO3  80 Da) indicated that Mnd2 was phosphorylated
on at least four to five different sites (384 	 80 Da) during M
phase and only one site on average (101 	 80 Da) during G1
phase. Furthermore the 283-Da mass difference observed
between themodified states ofMnd2measured in the phospha-
tase assay corresponded very well with the measured mass dif-
ference of 298 Da determined with Mnd2 purified from
nocodazole-arrested cells. Although these data indicate a spe-
cific number of phosphate modifications on Mnd2, it has been
our experience that these values are usually underestimates of
the total number of phosphorylation sites of a protein possibly
due to modification site heterogeneity and also due to the res-
olution of MALDI-TOF MS in the linear mode. Attempts to
measure the intact protein mass by electrospray ionization MS
were not successful. We conclude that Apc1 and Mnd2 are
phosphorylated subunits of the budding yeast APC.We further
conclude that Mnd2 phosphorylation is cell cycle-dependent.
Characterization of Mitotic Mnd2 Phosphorylation Sites—
Weused a combination ofMS-based approaches to identify the
phosphorylation sites inMnd2 protein fromMphase cells. Sur-
prisingly tandem MS analysis of Mnd2 peptides revealed only
one ion at m/z 2823.1 that could be assigned to the tryptic
Mnd2 monophosphopeptide 140AQNAEGNNEEDFRQH-
DpSREEDPR162 where pS is phosphoserine (Fig. 2A). The tan-
dem mass spectrum contained a number of b and y fragment
ions from theMnd2 peptide including some in which there was
a distinct neutral loss of phosphate (H3PO4) corresponding to a
mass shift of 98 Da. We also assigned a second ion of very low
intensity, m/z 1807.8, to the Mnd2 monophosphopeptide
258IVPDDLLMRPTSLSR272 (Table 2). However, the low inten-
sity of the fragment ions did not allow us to determine which of
the three possible phosphorylation sites (underlined) was occu-
pied (data not shown). Repeating this experiment and including
a G1-arrested sample for comparison, we found that phospho-
rylation at Ser156 occurred only during M phase (Fig. 2B). Sim-
ilarly no phosphorylation was observed during G1 phase for
peptide Mnd2-(258–272) (data not shown).
Based on our initial MS analysis, we could assign peptides
to 70% of the Mnd2 sequence by mass fingerprinting and
tandem MS but found only two phosphorylation sites. The
remaining 30% of Mnd2 sequence included two theoretical
tryptic peptides, 170VILPHILQENEEYDTGEGVTGLHSM-
PNDSMAILANNSANNSQNEEVSEEDEISYDYDAEFDHV-
VDEDDNEEGEVPGEGVEGIEVQR255 (m/z 9525), and
287NPYDIDSDNDGEDSK301 (m/z 1683.6), that contain a total
of 10 potential serine or threonine phosphorylation sites. We
did not detect the peptide Mnd2-(287–301) (including hypo-
thetically post-translationally modified forms) in our initialMS
analysis, although its theoretical mass falls between the optimal
range of detection for reflectronmodeMALDI-TOFMS,which
is betweenm/z 800 and 4000. We made this observation more
than once during repeat experiments withMnd2 fromMphase
cells (data not shown). We suspected that the difficulty in
detecting peptides within these regions of Mnd2 could be due
to their high Asp/Glu content, which can affect peptide ioniza-
tion in the mass spectrometer, as well as phosphorylation,
which can also affect peptide ionization and inhibit tryptic
digestion at cleavage sites that neighbor a phosphorylated
residue.
We used linear mode MALDI-TOF MS, which allows the
detection of high mass protein species, to search for the large
tryptic peptide Mnd2-(170–255) as well as any miscleaved
tryptic peptides that contained Mnd2-(287–301). Using this
approach, four major species of interest were detected at m/z
6618, 6688, 8393, and 9838, none of which could be assigned to
the unmodified Mnd2 sequence. Comparison of the spectra
with and without phosphatase treatment showed that each of
the four species was phosphorylated as indicated by negative
shifts in the apex mass after phosphatase treatment (Fig. 2C).
Using the apex mass of the ion species after phosphatase treat-
ment, we were able to assign each peptide to Mnd2 as well as
calculate the average number of occupied phosphorylation sites
within each peptide (Table 2). The tryptic peptides assigned to
m/z 6618, 6688, and 8393 each contained multiple missed
cleavage sites and included the tryptic regionMnd2-(287–301)
with one or two occupied phosphorylation sites. Because we
were able to detect each of the tryptic peptides flanking the
Mnd2-(287–301) region in the reflectron mode MS analysis
and confirm that they were unmodified, we concluded that the
occupied phosphorylation sites are Ser293 and Ser300. The ion at
m/z 9838 was assigned to the largest tryptic peptide, Mnd2-
(170–255), and contained an average of four occupied phos-
phorylation sites. The mass accuracy of this assignment was
within 7 Da of the expectedmass, likely reflecting an average of
a mixture of the unmodified peptide (m/z 9519) and a mono-
oxidized peptide (m/z 9535) because no other peptides with up
to 10 missed cleavages could be closely matched to this ion.
Calculation of the apex mass shift after phosphatase treatment
indicated that Mnd2-(170–255) contains an average of four
phosphorylated sites out of eight potential serine or threonine
residues. A comparison of these phosphopeptides in G1 phase
showed thatMnd2maintains partial phosphorylation (Fig. 2D).
In summary, we found that Mnd2 is phosphorylated on at least
eight different sites during mitosis and at least four sites during
G1 phase.
YeastHarboringMnd2Phosphorylation SiteMutationsGrow
Normally—Cell cycle-dependent phosphorylation is an impor-
tant component of APC-mediated cell cycle progression. Yeast
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FIGURE 2. MS identification of Mnd2 phosphopeptides purified from M phase cells. A, tandem MS spectrum of m/z 2823.1 corresponding to the mono-
phosphopeptide Mnd2-(140 –162). B, comparison of phosphorylation at Ser156 in M phase (cells arrested with temperature shift) and G1 phase. In this
experiment, m/z 2823.1 was not found; rather a shorter form (Mnd2-(153–162)) containing only one missed cleavage was found that was confirmed by tandem
MS. C, overlaid linear mode MALDI-TOF mass spectra of high molecular weight tryptic Mnd2 phosphopeptides from M phase-arrested cells before (solid line)
and after (dashed line) treatment with alkaline phosphatase (AP). The average estimation of occupied phosphorylation sites is indicated by the shift after
treatment with alkaline phosphatase. Note that the alkaline phosphatase-treated masses are all oxidized. D, same as C but from G1 phase-arrested cells. Note
that the alkaline phosphatase-treated peptide Mnd2-(170 –255) contains two oxidized methionine residues rather than one, resulting in a slight shift in the
mass spectra compared with that in C. pS, phosphoserine.
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strains harboring altered forms of theAPC that cannot bemod-
ified by phosphorylation display growth defects associated with
a delay in mitotic progression (26). To determine whether
Mnd2 phosphorylation is critical to the progression of mitosis,
we compared growth rates of anmnd2 strain inwhich thewild
type (WT) isoform or phosphorylation site mutant isoforms of
MND2 (mnd2-(S/T-A) andmnd2-(S/T-D)) were introduced at
the trp1 locus under control of the MND2 promoter (see
“Experimental Procedures”). Mnd2 mutants were created by
simultaneously mutating all 14 sites found or implicated by our
MS analysis to alanine or aspartic acid (aspartic acid mutations
are meant to mimic the phosphorylated state of Mnd2). As a
positive control for the growth rate of strains harboring anAPC
defect, we compared the growth rate of yeast lacking Apc10,
which display a slow growth phenotype due to compromised
APC processivity (33, 34). Growth rates for all but the apc10
strain were indistinguishable at both 30 and 37 °C (Fig. 3). This
observation was not surprising because the mnd2 strain dis-
plays no significant difference in growth rate compared with
the wild type strain (34, 47).We conclude that phosphorylation
at the sites found in our MS analysis do not have a significant
function in the proper progression of mitosis.
Mitotic Mnd2 Phosphorylation Is Required for Progression
through the First Meiotic Nuclear Division—Yeast lacking
Mnd2 are incapable of sporulation and arrest after the comple-
tion of premeiotic S phase but before the first meiotic nuclear
division (30, 31, 35). To determine whether Mnd2 phosphoryl-
ation is required for sporulation, we compared the phenotypes
ofWT,mnd2,mnd2-(S/T-A), andmnd2-(S/T-D) strains upon
induction of sporulation. When comparing the kinetics of tet-
rad formation for each strain, we found that 85% of WT cells
formed complete tetrads within 42 h after plating to sporula-
tion medium; this was nearly identical to the sporulation per-
centage for cells harboring MND2 at its natural genetic locus
(Fig. 4A). In contrast, mnd2 strains were unable to form tet-
rads. Only 13% of cells harboring mnd2-(S/T-A) formed tet-
rads, whereas the percentage of tetrads increased to 42% of cells
harboring mnd2-(S/T-D). In addition, as observed by light
microscopy, there was no appreciable accumulation of cells
containing only two spores (dyads), which would have indi-
cated arrest between the first and second nuclear division. The
differences in tetrad formation between the WT and mutant
strains was not due to a failure in meiotic entry because each
strain completed premeiotic S phase as measured by flow
cytometry (Fig. 4B).
Quantitation of tetrad formation cannot be used as an indi-
cator for the ability of cells to complete meiotic nuclear divi-
sions. Indeedmeiotic nuclear divisions and spore formation are
not completely connected pathways, and it is possible to
achieve nuclear divisions without forming spores, which has
been reported for subpopulations of ama1 cells (29). Cells
that do not undergo the first meiotic nuclear division arrest
with a single nucleus that can be visualized using fluorescence
microscopy of DAPI-stained nuclei. To determine whether
meiotic nuclear divisions were compromised in the mnd2
FIGURE 3. Yeast harboring phosphorylation site mutations grow nor-
mally. Logarithmic plots of vegetative growth rates relative to the 2-h time
point measured in YPD medium for WT, mnd2-(S/T-D), mnd2-(S/T-A), mnd2,
and apc10 at 30 °C (left) and 37 °C (right). Data were averaged from triplicate
experiments.
TABLE 2
Assignment of Mnd2 phosphopeptides
Masses of the dephosphorylated peptides were used for assigning Mnd2 sequence to each MS ion with the exception ofm/z 1808.8 andm/z 2823.1 that were assigned by
tandemMS sequencing. Mass of the phosphorylated peptide (mp) was compared with the mass of the dephosphorylated peptide (mdp) to determine the average number of
phosphorylation sites occupied (Avg. no.HPO3). The assignedMnd2 peptide sequence, additional observedmodifications after phosphatase treatment (Add.mod.), and the
expected average masses (m) are shown. The mass accuracy is shown as the difference between the dephosphorylated peptides and the expected average mass (mdp  m)
with the exception of m/z 1808.8 and m/z 2823.1 whose error was calculated from the expected phosphorylated mass. pS, phosphoserine; Calc. avg., calculated average;
MetOx, oxidized methionine. pS, phosphoserine; bold, phosphorylation sites implicated by MS analysis; underlined, possible phosphorylation sites that could not be
localized to specific residues.
Observed
masses m ( mp  mdp)
Avg. no.
HPO3
Assigned Mnd2 peptide sequence Add. mod. Calc. avg.mass (m) Error (mdp  m)
mp mdp
1808.8 1 258IVPDDLLMRPTSLSR272 1808.8 0.09
2823.1 1 140AQNAEGNNEEDFRQHDpSREEDPR162 2823.1 0.01
6618 6531 87 1 287NPYDIDSDNDGEDSKVELDMNPDFEDD
VGREHDYNSEYSQEPTSYGGITPDLAS
NWR343
1 MetOx 6531 0
6688 6531 157 2 287NPYDIDSDNDGEDSKVELDMNPDFEDD
VGREHDYNSEYSQEPTSYGGITPDLAS
NWR343
1 MetOx 6531 0
8393 8225 168 2 273SLQQFVEEAHHLDRNPYDIDSDNDGED
SKVELDMNPDFEDDVGREHDYNSEYSQ
EPTSYGGITPDLASNWR343
1 MetOx 8223 2




0–1 MetOx 9525 7
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phosphomutant strains, we scored the percentages of non-tet-
rad-forming (residual) cells that contained a single undivided
nucleus after 48 h on sporulation medium. In strains harboring
mutant or wild type Mnd2, the percentage of non-tetrad cells
containing a single undivided nucleus was greater than 90%
(Fig. 4C). Because tetrads are formed at low levels in strains
harboringmnd2-(S/T-A), we also quantified the viability of tet-
rad spores. A high percentage of spore viability indicates that
cells are capable of proper nuclear divisions that distribute a
complete complement of the haploid genome to each spore.
Low spore viability is observedwhen nuclear divisions are com-
promised such that individual spores are left with an incom-
plete complement of the haploid genome. Following tetrad dis-
section, 95% of WT spores were viable compared with 89 and
84% spore viability for mnd2-(S/T-D) and mnd2-(S/T-A) cells,
respectively (Fig. 4C).
The proteins Pds1 and Clb5 fail to accumulate appreciably
in sporulating mnd2 cells due to unrestrained APCAma1
activity during meiosis (30, 31). To ascertain whether the
phosphorylation status of Mnd2 affects its function as an
APCAma1 inhibitor, we compared the protein stability of
Clb5 in cell extracts taken from a sporulation time course.
Sporulating cells were collected at 0, 24, and 48 h, and the
percentages of tetrad-forming cells and cells with replicated
DNA were quantified to verify synchrony and meiotic entry
of each strain (Fig. 4D, top). Clb5 levels were low to immea-
surable in the mnd2 strain compared with the WT strain
(Fig. 4D, bottom). Very little accumulation of Clb5 was
observed for the mnd2-(S/T-A) strain, but accumulation of
Clb5 was noticeably higher in the mnd2-(S/T-D) strain. A
similar trend was observed for Pds1 (data not shown). Taken
together, these data show that phosphorylation of Mnd2 is
critical for efficient progression through the first meiotic
nuclear division and for normal accumulation of the
APCAma1 substrate, Clb5. We conclude that phosphoryla-
tion of Mnd2 is necessary for inhibition of APCAma1 in early
meiosis.
Mnd2 Phosphomutants Display Differential Co-precipitation
with the APC in Vivo but Not in Vitro—Althoughmitotic phos-
phorylation ofMnd2 is necessary for progression through early
meiosis, it is clearly not essential for normal cell growth,making
it difficult to explain the reason why Mnd2 phosphorylation
occurs during the mitotic cell cycle. Previous reports suggest
that Mnd2 can only inhibit the APC when it is present on the
complex (30). Therefore, one possible explanation for our
results is that phosphorylation of Mnd2 affects its binding to
the APC. First we compared the levels of each Mnd2 isoform
after affinity purification of the APC fromWT,mnd2,mnd2-
(S/T-A), ormnd2-(S/T-D) strains (Fig. 5A). ComparativeWest-
ern blot analysis revealed that the alaninemutantwas undetect-
able, similar to an mnd2 strain. In contrast, the aspartic acid
mutantwas detectable but at a lower level than theWT isoform.
Together the relative difference in abundance of each Mnd2
isoform was directly proportional to the observed relative dif-
ference in sporulation and Clb5 levels for eachMND2 isoform
strain (compare with Fig. 4, A and D). Interestingly the abun-
dance of WT Mnd2 in these experiments was low when com-
pared with a WT strain expressing Mnd2 from its endogenous
genetic locus (data not shown) in which case Mnd2 is stoichio-
metric with other APC subunits (48). This suggests that subs-
toichiometric levels of Mnd2 are sufficient to inhibit APCAma1
and allow normal meiotic progression because our WT inte-
grant strain exhibited identical sporulation kinetics compared
with theWT strain whereMnd2 was expressed from its endog-
enous genetic locus.
In contrast to our in vivodata, we found that binding between
APCmnd2 and recombinant WT GST-Mnd2, GST-mnd2-(S/
T-A), or GST-mnd2-(S/T-D) was almost constant in compari-
son with a control in which only GST was present (Fig. 5B). In
fact, binding of the aspartic acid isoform was slightly weaker
than either theWTor alanine isoform,which is counter towhat
would be expected based on the more proficient sporulation of
yeast harboring the aspartic acidmutant. These in vitro binding
results support our earlier data, which showed that Mnd2
remains associated with the APC before and after phosphatase
treatment (Fig. 1D). Taken together, these data suggest that
mitotic phosphorylation is not required for association of
Mnd2 with the APC and that binding between the APC and
mnd2-(S/T-A) ormnd2-(S/T-D) is similar in vitro. Furthermore
the difference in results for the in vivo co-precipitation assay
versus the in vitro binding assay suggests that mitotic Mnd2
phosphorylation may function in an unknown regulatory
mechanism that is necessary to ensure proper levels of APC-
bound Mnd2 prior to meiotic entry when APCAma1 becomes
active.
DISCUSSION
We used a mass spectrometric approach to discover and
identify mitotic phosphorylation sites on the APC subunit
Mnd2. The phosphorylation status of Mnd2 appears to be gen-
erally similar to that of other phosphorylated yeast APC sub-
units (Cdc16, Cdc27, andCdc23) in that it was higher inmitosis
compared with G1 phase. Interestingly none of the phos-
phopeptides observed contain the canonical cyclin-dependent
kinase recognition sequence (S/T)P suggesting the involvement
of other kinases. Mutation of Mnd2 phosphorylation sites had
no effect onmitotic cell cycle progression; this is not surprising
considering that Mnd2 has no required function during vege-
tative cell growth. However, there was a striking difference in
the ability of Mnd2 phosphorylation site mutants to complete
meiosis. The similarities in sporulation defect for the alanine
and deletion mutant strains strongly suggest that phosphoryla-
tion is critical for Mnd2 function early in the meiotic program.
Both strains completed premeiotic S phase, and like the dele-
tion strain, the majority of alanine mutants failed to undergo
the first meiotic nuclear division. In addition to a meiotic spor-
ulation defect, we also found thatmnd2-(S/T-A)mutants have
lower levels of the APCAma1 substrate, Clb5, which suggests
that mitotic phosphorylation of Mnd2 is necessary to maintain
its APC inhibitory function rather than an effect unrelated to
APC activity. Mutation of each phosphorylation site to aspartic
acid, which may mimic the phosphorylated state of Mnd2, par-
tially suppressed the sporulation defect and further supported
the conclusion that phosphorylation is necessary for Mnd2
function in early meiosis.
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The difference in sporulation of strains harboring different
Mnd2 isoforms does not appear to be due to a difference in
binding between Mnd2 and the APC. In vitro, WT Mnd2,
mnd2-(S/T-A), and mnd2-(S/T-D) are each capable of binding
the APC with similar affinities. Furthermore phosphorylation
of WT Mnd2 is not necessary for its association with the APC
because treatment of M phase or G1 phase APC with phospha-
tase did not eliminate Mnd2 binding. In vivo, the co-precipita-
tion of each Mnd2 isoform with the APC was strikingly differ-
ent and correlated well with the observed differences in
sporulation and Clb5 levels for each strain. Taken together,
these data do not support a role for mitotic Mnd2 phosphoryl-
ation in the direct regulation of APCAma1 ubiquitin ligase activ-
ity. Rather mitotic Mnd2 phosphorylation appears to be
involved in a mitotic process that is independent of Ama1 but
that has significant implications on the cell cycle once Ama1 is
expressed at the beginning of meiosis, similar to the defects
observed when Mnd2 was absent.
Despite its overall similarities to the deletion strain, some
cells harboring mnd2-(S/T-A) are still capable of complete
sporulation resulting in the formation of viable haploid spores.
Thus, eliminating mitotic Mnd2 phosphorylation at the sites
we discovered did not completely abolish the inhibitory func-
tion ofMnd2. Furthermore the high percentage of spore viabil-
ity in the phosphomutant strains also suggests that mitotic
phosphorylation ofMnd2 is only necessary before the first mei-
otic nuclear division because mutant cells that do form tetrads
must be capable of completing normal meiotic nuclear divi-
sions and spore formation. This observation is consistent with
existing data that show that Mnd2 is necessary for the comple-
tion of recombination before the first meiotic nuclear division
(30, 31). Conversely cells harboring mnd2-(S/T-D) were not
capable of completely suppressing the sporulation defect of
mnd2 cells; this may be due to insufficient mimicry of phos-
phorylation by the side chain of aspartic acid.
Two different hypotheses could explain the difference in
APC/Mnd2 association observed in our in vivo co-precipitation
experiments compared with our in vitro APC binding assay. 1)
Mitotic phosphorylation may be necessary to block the associ-
ation of “seclusion factors” that could function to inhibit the
association of Mnd2 with the APC in vivo. 2) Phosphorylation
may be necessary to inhibit the degradation of Mnd2 during
mitosis. Currently there is no evidence in support of the first
hypothesis, although it has never been tested directly. With
regard to the second hypothesis, others have found that phos-
phorylation can protect proteins from various forms of degra-
dation including direct enzymatic proteolysis (49, 50) as well as
ubiquitin-mediated proteolysis (51, 52). Consistent with this
hypothesis, a decrease in the stability of Mnd2 would be
expected to mimic an mnd2 sporulation defect due to unin-
hibited APCAma1, similar to what we saw with the mnd2-(S/
T-A)mutant. In addition, evidence forMnd2 regulation by deg-
radation has been suggested previously (30, 31) where it was
shown that the inhibitory function ofMnd2 is regulated in part
by degradation that occurs late in meiosis after anaphase II and
thatmay requireMnd2 phosphorylation (30, 31). Amechanism
similar to that which occurs in late meiosis may also exist dur-
ing mitosis and would provide an interesting explanation for
the role of mitotic Mnd2 phosphorylation.
The kinase(s) that phosphorylate Mnd2 remain unknown.
Indeed the phosphorylation ofMnd2 duringmitosismay not be
caused by the same kinases responsible for its phosphorylation
during meiosis. Currently the primary kinases known to phos-
phorylate the APC are cyclin-dependent kinase (Cdc28 in
yeast) and polo-like kinase Cdc5. However, none of the Mnd2
phosphopeptides thatwe observed contained either a canonical
cyclin-dependent kinase recognition sequence ((S/T)P) or the
polo box domain recognition sequence (S(pS/pT)P where pT is
phosphothreonine). Notablymany of the phosphorylation sites
implicated by our MS analysis fell within regions of high Asp/
Glu residue content, which could suggest phosphorylation by
casein kinase 2 (53).
FIGURE 4. Phosphorylation of Mnd2 is necessary for efficient progression through the first meiotic nuclear division. A, kinetics of tetrad formation for
WT, mnd2-(S/T-D), mnd2-(S/T-A), and mnd2 cells. Tetrad formation kinetics for a wild type strain in which MND2 is expressed from its normal locus is shown (*).
B, kinetics of premeiotic S phase measured by flow cytometry. C, differential interference contrast (DIC) and fluorescence microscopy of DAPI-stained yeast 42 h
after plating on SPM. The percentage of tetrads formed, the percentage of non-tetrad (residual) cells with a single nucleus, and the percentage of viable spores
are indicated to the right of each microscopy image. D, percentage of tetrad-forming cells 24 and 48 h after plating on SPM (top, left), percentage of cells with
replicated DNA at 0, 24, and 48 h after plating on SPM (top, right), and Western blot comparison of Clb5 levels in extracts prepared and quantified after lysis of
cells harvested at 0, 24, and 48 h after plating on SPM. A nonspecific band detected in the Western blot is shown as a loading control. The bar graph shows
quantitation of Clb5 levels from the Western blot. Normalized band intensities were calculated by taking the ratio of Clb5 signal to the corresponding loading
control band for each lane. The data are shown after subtraction of the normalized intensities of the deletion strain for each corresponding time point.
FIGURE 5. Mnd2 phosphomutants display differential co-precipitation
with the APC in vivo but not in vitro. A, co-precipitation of WT and Mnd2
phosphorylation site mutants with the APC in vivo. APC was purified from
normalized yeast extracts generated from 1-liter cultures grown to A600  1.0
via Cdc27-3 FLAG. Detection of Mnd2 was achieved using a customized
rabbit polyclonal antibody to the N terminus of Mnd2. B, in vitro binding assay
between GST-Mnd2 WT, mnd2-(S/T-A), mnd2-(S/T-D), and GST. APC was puri-
fied from CDC27-3 FLAG mnd2 cells harvested from an asynchronous mid-
log phase culture and incubated in batch with an excess of GST-Mnd2 fusion
protein bound to GSH-Sepharose. Unbound protein was washed away with
100 bead-equivalent volumes of buffer, and the bound protein was eluted in
1 bead-equivalent volume of SDS-PAGE loading buffer. The input, flow-
through (FT), and elution (E) are shown after Western blotting with anti-FLAG
or ant-GST antibodies. IP, immunoprecipitate; WB, Western blot.
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In addition to our discovery of Mnd2 phosphorylation, we
also showed that Apc1 is phosphorylated during mitosis. Pre-
liminary experiments showed that Apc1 is phosphorylated on a
number of sites that are containedwithin a canonical cyclin-de-
pendent kinase recognition sequence as well as some sites that
are not.3 Further workwill focus on characterizing these sites at
different cell cycle stages and determining their role in APC-
mediated mitotic and meiotic progression.
We showed that phosphorylation sites occupied differen-
tially during themitotic cell cycle can provide critical regulatory
roles for the APC during meiosis. To our knowledge, this is the
first case in which mitotic APC phosphorylation site mutants
have been tested inmeiosis. The fact that phosphorylation sites
between the two types of nuclear division are shared in this way
suggests that knownmitotic phosphorylation sites within other
APC subunits may also be required for meiosis. Future experi-
ments that characterize the dynamics of APC phosphorylation
during mitosis and meiosis will likely be invaluable to our
understanding of APC regulation.
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